PHASE 1B, OPEN-LABEL, MULTI-CENTER STUDY TO CHARACTERIZE THE SAFETY, TOLERABILITY AND PHARMACODYNAMICS (PD) OF PDR001 IN COMBINATION WITH CJM112, EGF816, ILARIS (CANAKINUMAB) OR MEKINIST (TRAMETINIB)
- Registry ID
- CPDR001X2103
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- NOVARTIS PHARMACEUTICALS CANADA INC
- Start date
- 2018-03-05
- Last update
- 2016-06-30
Conditions
- NON-SMALL CELL LUNG CANCER
- COLORECTAL CANCER
- BREAST CANCER TRIPLE NEGATIVE
Related clinical trials
- A RANDOMIZED, OPEN LABEL, 3-ARM PHASE 3 STUDY OF PRECEMTABART TOCENTECAN WITH OR WITHOUT BEVACIZUMAB COMPARED TO TRIFLURIDINE/TIPIRACIL PLUS BEVACIZUMAB IN PARTICIPANTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER (PROCEADE-CRC-03)
- A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ADJUVANT INTISMERAN AUTOGENE PLUS SUBCUTANEOUS PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA MK-3475A) OR INTISMERAN AUTOGENE MONOTHERAPY VERSUS PLACEBO IN PARTICIPANTS WITH COMPLETELY RESECTED HIGH-RISK STAGE I NON-SMALL CELL LUNG CANCER (INTERPATH-014)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ADJUVANT MK-1084 PLUS SUBCUTANEOUS PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA (MK-3475A) VERSUS ADJUVANT PLACEBO PLUS MK-3475A IN PARTICIPANTS WITH COMPLETELY RESECTED STAGE IIA-IIIB (N2), KRAS G12C-MUTANT NON-SMALL CELL LUNG CANCER FOLLOWING RECEIPT OF EITHER NEOADJUVANT PEMBROLIZUMAB PLUS CHEMOTHERAPY OR ADJUVANT CHEMOTHERAPY (KANDLELIT-013)
- KONTRAST-R: AN OPEN-LABEL, MULTI-CENTER, ROLLOVER STUDY FOR PARTICIPANTS WHO HAVE BEEN PREVIOUSLY ENROLLED INTO A NOVARTIS-SPONSORED OPNURASIB (JDQ443) STUDY AND ARE CONTINUING TO BENEFIT FROM OPNURASIB AS A SINGLE AGENT OR IN COMBINATION WITH OTHER STUDY TREATMENTS
- AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
- A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MK-1084 IN COMBINATION WITH SUBCUTANEOUS PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA (MK-3475A) VERSUS MK-3475A IN COMBINATION WITH PEMETREXED/PLATINUM (CARBOPLATIN OR CISPLATIN) CHEMOTHERAPY AS FIRST-LINE TREATMENT OF PARTICIPANTS WITH KRAS G12C MUTANT, ADVANCED OR METASTATIC NONSQUAMOUS NSCLC (KANDLELIT-007)
View on source registry